A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent or newly diagnosed glioblastoma

Presented at 2023 SNO Annual Meeting

Patrick Roth¹, Kyriakos P. Papadopoulos², Maria Vieito^3,4, Jonathan T. Yang⁵, Nazanin K. Majd⁶, Juan Manuel Sepulveda⁷, Lauren R. Schaff⁸, Victor Moreno⁹, Jaime Gállego Pérez-Larraya¹⁰, Sandrine Micallef¹¹, Anne Bellon¹¹, Mokhtar Omar¹¹, Esteban Rodrigo Imedio¹¹, Luke Piggott¹¹, Victor Rodriguez-Freixinos¹¹, Jordi Rodon¹²

1 Department of Neurology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland
2 START San Antonio, San Antonio, TX, USA
3 Vall d’Hebron Institute of Oncology, Barcelona, Spain
4 Universidad Autonoma de Barcelona, Barcelona, Spain
5 Department of Radiation Oncology, University of Washington Fred Hutchinson Cancer Center, WA, USA
6 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
7 Hospital Universitario 12 de Octubre, Madrid, Spain
8 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York
9 START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
10 Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain
11 Debiopharm, Lausanne, Switzerland
12 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA